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Phosphorylation of cyclin-dependent kinases (CDKs)
by the CDK-activating kinase is required for the activa-
tion of CDK enzymes. Members of two families of CDK
inhibitors, pI6/piS and p211p27, become physically asso-
ciated with and inhibit the activity of CDKs in response
to a variety of growth-modulating signals. Here, we
show that the representative members of both families
of CDK inhibitors, p2Iwa/1,cip Z, p27k ip Z, and pIS, can pre-
vent the phosphorylation of their CDK partners, CDK2
and CDK6, by CDK-activating kinase. No direct interac-
tion between CDK-activating kinase and the CDK inhib-
itors could be detected, suggesting that binding of these
CDK inhibitors to CDK subunits renders CDK inacces-
sible to the CDK-activating kinase phosphorylation.
These findings suggest that a general mechanism of
CDK inhibitor function is to block the phosphorylation
of CDK enzymes by CDK-activating kinase.
The primary control of the eukaryotic cell cycle is provided by
a family of serine/threonine protein kinases known as cyclin-
dependent kinases (CDKs).l The enzymatic activity of a CDK is
regulated at three different levels: cyclin binding and activa-
tion, subunit phosphorylation, and inhibition by a group of
heterologous small proteins. Phosphorylation of Thr-I6I (or
Thr-I60 in CDK2) is required for p34cdc2/p33cdk2 activation (1,
2). The enzyme that causes the phosphorylation of p34cdc2,
p33 cdk2, and perhaps other members ofCDK family on Thr-I6I,
termed CDK-activating kinase (CAK) (3-7). In mammalian
cells, the catalytic subunit of CAK, CDK7, is associated with
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and activated by a regulatory subunit, cyclin H (8, 9). CDK
activity is also regulated by a number of small proteins that
physically associate with cyclins, CDKs, or their complexes.
There exist at least two distinct families of CDK inhibitors in
mammalian cells: the p2I/p27 family and the pI6/p18 family.
p21 and p27 proteins share considerable sequence homology
and have been shown to be a potent inhibitors of almost all
cyclin-CDK enzymes (8-18), In contrast, the p16 family ofCDK
inhibitors specifically interacts with the D-type cyclin-depend-
ent kinases 4 and 6 (CDK4 and CDK6). The p16 family cur-
rently includes four isolated genes that share sequence simi-
larity and were evolved from a common ancestor,
p16INK4AIMTSl (19), pI4/pI5MTS2IINK4B (20, 21), p18 (21), and
p20.2 The prototype member of this family, p16, is homozy-
gously deleted at a high frequency in a wide variety of human
tumor-derived cell lines (23, 24) and is also mutated or deleted
in several specific types of primary tumors (25-29).
Direct physical interaction between CDK inhibitors and
CDK enzymes is necessary for CDK inhibition, but the precise
mechanism remains to be elucidated. We asked whether CDK
inhibitors would affect CDK phosphorylation by CAK. Here, we
show that CAK phosphorylation of CDK2 is prevented by the
CDK inhibitors, p21 and p27, and that the inhibition of CAK
activity by p21 or p27 does not appear to involve a direct
interaction between CAK and p2I or p27. In addition, we find
that the CDK6-specific inhibitor p18 belonging to the p16 fam-
ily of CDK inhibitors also blocks CAK phosphorylation of
CDK6.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture Synchronization-Primary human fore-
skin fibroblasts (NHF) cultivation, serum starvation, and serum stim-
ulation were performed as described in Ref. 30.
Antibodies to Human CDK7-Polyclonal antibodies were raised in
rabbits against C-terminal131 amino acids (see Ref. 31). Corresponding
fragment was PCR-amplified and subcloned into a pQE31 vector
(Qiagen, Chatsworth, CAl as a BamHI-KpnI fragment. Antigenic
polypeptide was expressed in bacteria as a hexahistidine-tagged recom-
binant protein and purified according to Qiagen instruction. Antisera
was affinity-purified using bacterially expressed antigenic polypeptide
bound to Ni2 + -NTA-agarose (Qiagen). 1 ml of the antibodies was loaded
into the column, the column was extensively washed with phosphate-
buffered saline, and antibodies were eluted with 1 ml of ActiSep media
(Sterogene, Arcadia, CAl and desalted according to manufacturer's
instructions.
Construction of Mutagenic Recombinant CDK6-To replace threo-
nine 177 in GST-CDK6 for alanine, the fragment containing two unique
sites (SphI and DraIIl) was PCR-amplified using forward primer with
SphI site: 5'-CGAGGAGGGCATGCCGCTCT-3' and reverse mutagenic
oligonucleotide with DraIII restriction site: 5' -GTACCACAGCGTGAC-
GACCACTGAGGCTAGAG-3'. The PCR fragment was digested with
SphI and DraIII and inserted into SphliDraIII-cut GST-CDK6. The
presence of mutation was confirmed by sequencing reaction.
Purification of Recombinant Proteins from Bacteria-GST-cyclins A
and D were purified according to Solomon et al. (1). GST-CDK2 and
GST-CDK6 were purified according to Poon et al. (5). Purification of
bacterially expressed CDK inhibitors will be described elsewhere."
Kinase Assay-Cell lysates (100 /kg of total protein) prepared in
Nonidet P-40 lysis buffer (10) were used for immunoprecipitation with
anti-CDK7 antibodies. CAK activation of GST-CDK2 and direct phos-
phorylation of GST-CDK2 were performed as in Ref. 5. To test an effect
2 K. L. Guan, C. W. Jenkins, Y. Li, M. Zariwala, S. Noh, X. Wu, and
Y. Xiong, submitted for publication.
3 D. R. Mayrose, M. A. Nichols, Y. Xiong, and H. Ke, submitted for
publication.
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F IG. 1. p21 a n d p27 d o not d ir ectly inh ibit CAK a ctivity. Ex-
tra cts of NHF cells were incubat ed with indicated qu ant ities of p21 or
p27 and imm unoprecipit at ed with anti-CDK2 (A) or anti-CDK7 (13)
antibodies . The kin ase activity of imrnunoprecipita te d CDK2 was meas-
ured by histone H I phosphorylation (A), and th e kina se activity ofCAK
was measur ed by GST-CDK2 phospho ryla tion un Lanes 1 of both A
and 13 show the immunoprecipitated CDK2 or CAK activit ies from th e
lysa tes in the absence of CDK inh ibitors. In lanes 2 of both A and 13 ,
anti·C DK2 or anti-C DK7 antibodies wer e blocked with corr espondent
antigenic peptides before immunopreci pita tion. Of note is th e fact that
none of the CDK inhibitors block the imm un oprecipit at ion of CDK2.
wit h a CDK may rend er the threonine at position 160 (in
CDK2, or 161 in CDC2) inaccessib le to the CAK enzy me,
the reby preventing th e phosph oryla tion and activation of the
CDK. To test th is possibility, we assemb led the CDK2-cyclin A
comp lex in vitro usin g bacteri all y expressed and purified GST·
CDK2 and GST-cyclin A and used this complex to determ ine
possib le effect of p21 and p27 on CDK2 phosphorylation by
CAK. Int r igu ingly, th e addit ion of the p21 or p27 proteins to
th e CDK2-cyelin A complex dram atically decreased CDK2
phosph orylation by CAK (Fig. 2, A and 8). To further address
the specificity of p21 and p27 inhibition of CDK2 phosp horyl-
ati on by CAK, and to exclude th e possibility th a t this inhibi tion
may be caused by a trac e amount of Escherichia coli protein s
copurifying with the p2I or p27 protein s, we tested the effect of
another newly identified CDK inhibitor, p18, on CDK2 phos-
phoryla tion by CAK. p18 is a homolog of p16 th at st rongly
inhibits the activity of CDK6 and wea kly inhibits th at of CDK4,
but exhibits no detectab le interaction with four oth er CDKs
includ ing CDK2 (21). When we applied a recombina nt p18
protein that was prepared in a mann er simila r to th at for p21
and p27, no inhibi tion of CDK2 phosp horylation by CAK was
det ected (Fig. 2C). The same resu lt was obtained when we
added bovine seru m albumin instead of CDK inhibitors in the
reaction (Fig. 2D ). These resu lts indi ca te tha t inhibiti on of
CDK2 phosp horylat ion by CAK is depend ent on p21/p27 and
not on p18.
Th e differ ences between two famil ies of CDK inh ibit ors raise
an important quest ion of whet her the p16 fam ily of CDK in-
hib itors can also block th e CAK phosph orylation on CDK. In
order to analyze the effect of the p16/p18 family of in hibitors on
CDK phosphorylati on by CAK, we first det ermined whether
the bacteria lly expressed GST-CDK6 protein could be phospho-
rylated and act iva ted by CAKlCDK7. Unlike CDK2 activat ion
that has been well studied, no data about phosp horyla tion and
activation ofC DK6 is availa ble. Fig. 3 (top pan el) shows that in
the absence of immunoprecipit ated CAK, no phosphoryla t ion of
CDK6 ta kes place. Some phosphoryla tion of GST-CDK6 can be
det ected when the recombinan t CDK6 is coincubated with CAK
in the absence of cyclin. However, the addi tion of GST-cyclin
Dl enhances CAK phosphorylation of CDK6 and renders th e
CDK6 enzymatically act ive in the phosph orylati on of the Rb
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Seque nce simila rity between CAK catalyt ic subunit CDK7
and CDKs initiall y prompted us to ask whether CDK7 cou ld
also be regula ted by the p21 CDK inhibitor. To addre ss thi s
question , we raised polyclonal antibodies agains t th e bacteri-
a lly expressed C-te rminal portion of human CDK7. This anti-
body was found not to cross-react with different memb ers of
CDK fam ily. The a nti-CAK immunoprecip it a tes possess kinase
activity toward GST-CDK2.As reported previously (5, 8 , 9),
CDK2 alone wit hout it s associated cyelin partner can be readil y
phosphorylated by CAK, but th e cyelin subunit is necessary for
the activation of the CDK2 histone HI kinase activi ty .Under
our conditions the amount of imm unoprecipitated CAK was a
limi ting factor, therefore phosphorylation of histone HI by
GST-CDK2-GST-cyclin A complex always corre la ted with phos-
phorylation of GST-CDK2 by CAK (data not shown ).
To test the potential effect of p21 on CAK activity, we first
assesse d whethe r p21 in teracts wit h the ca ta lyt ic subunit of
CAK, CDK7, as is the case for oth er CDKs. Norm al human
fibroblasts (NHF) synchronized at differen t ph ase of the cell
cycle by se ru m starva tion and re-stimulation were metaboli-
cally labeled wit h rl5S lmethionine and immunopr ecipitated
with antibody specific to CDK7. Th is experiment did not reveal
the presence ofa 21-kDa protein in anti ·CDK7 immunoprecipi-
tates. Fu r thermore, whe n anti-p21 immunopr ecipit a tes were
probed with antibodies agains t CDK7 we found no detectab le
CDK7 protein in asynchronously growing fibroblasts. Sim i-
la rly, when anti-CDK7 imm unoprecipa tes were probed with
anti bodies against p21, we found no p21 protein in fibroblasts
sy nchronized by serum sta rva t ion and restimulation . The same
results were also obtained in human lymphocytes st imula ted to
prolifera te by PHA a nd IL-2 trea tment (da ta not shown).
Sinc e it remained possible tha t the fa ilure to detect th e
presumptive p21-CAK assoc ia tion may have result ed from low
levels of CDK7 expression or from ant ibody disruption , we
tes ted the poten ti al direct in teraction of p21 and CAK by as-
sayi ng the act ivity of CAK in presence of high quan tities of
bacteria lly expressed p21. In these experiments we also used a
rela ted CDK inh ibitor p27 . When added to NHF cell lysates ,
purified recomb inan t p21 and p27 effect ively inhibited th e
hist one H I kinase activity of immunopr ecipita ted CDK2
(Fig. lA ). In contrast, no in hibit ion of CAK kinase activity (as
assessed by CDK2 phosp horylation) by p21 or p27 wa s detected
(Fig. I B ). Thus, from these data , we believe tha t neith er p21
nor p27 physically intera ct wit h CAK.
Although p21 an d p27 do not a ppear to intera ct wit h CAK
directly, it is still possible tha t the binding of CDK inhibitors
of CDK inhibitors, 1 /l g of GST-CDK2 and 1 /l g of GST-cyclin A were
mixed wit h p21 or p27 in amounts indica ted on the top of the pictu res
in a tot a l volume of 20 /ll in kinase buffer for 30 min on ice. Then 5 /l Ci
of Iy_:l2 P IATP was added, and the reaction mixture was t ra ns ferre d to
the tube wit h irnmu noprecipitated CAK for 10 min at 23 °C, followed by
SDS-polyacrylami de gel elect rophores is and autoradiogra phy.
Direct phosphorylat ion of GST·CDK6 by CAK was perform ed by
incuba tion of immunoprecipitated CAK (l00 /l g of tota l protein ) with
0.5 /l g ofGST-CDK6, 0.5 /l g of GST-cyclin Dl , and 10 /lCi ofl y .:l2 P IATP
for 40- 60 min at 30 °C in the kinase buffer. To assay for the act iva tion
of CDK6 by CAK, the first ste p was performed wit h 1 mxr cold ATP as
above. Then GST fusion protein with the 137 Cvtermi na l amino acids of
Rb (21) was add ed toget her with 10 /lCi of Iy _:l2 P jATP for anothe r 20
min a t 30 °C.
Direct Effect of p2 1 and p27 Oil CDK2 and CAK Activity- To ana lyze
direct effect of CDK inhi bitors on CDK2 or CAK (Fig. 1), 100 /l g of cell
lysates were incuba ted with indica ted amounts of p21 or p27 for 1 h at
4 °C. Then CAK or CDK2 were immunoprecipitated, washed two times
wit h lysis buffer and two times with kina se buffer, and act ivities
wer e mea sured using GST-C DK2 as a substrate for the anti·C DK7
immunopreci pitates or histone HI as a subst ra te fOJ' the ant i-CDK2
immunoprcc ipitates .
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FIG. 4. p1 8 inhibits GS T-CDK6 phosphoryl ation by CAK. In the
top panel , incr easin g amounts of pI S were pre-mixed with GST-cyclin
Dl and then added to GST-CDK6. Thi s complex was th en incubat ed
with irnmunoprecipit at ed CAK showing inhibition of CDK6 phosph o-
rylation by pI S. In th e bottom pan el, Rb phosph orylati on in presence of
pIS was test ed.
.. .. .. .. ., '" ..p21, IJ9 0 d :;: d P27. P9 0 d d d
A 32P-GST-COK2-8 B
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FIG. 2. p21 a n d p27 proteins inhibit CDK2 p hosphorylation by
CAK. Complexes of GST-CDK2, GST-cyclin A, and different amounts of
p21 (A) or p27 (8) were used as a subs trates for CAK immunoprecipi-
tated from NHF cells . pIS (C) or BSA (D) wer e mixed with GST-







FIG. 3. Immunoprecipitated CAK p hosphorylates GST-CDK6
a n d ac t iva tes it s Rb kinase acti v ity. Top panel, imrnu nopr ecipt at ed
CAK was incubat ed with [y-:l"PlATP and GST-CDK6 , in the ab sence
([ane 3) or presence ilane 4) of GST-cyclin Dl and analyzed by SDS-
polyacrylamide gel elect rophoresis and au tora diography. Bott om panel,
immunoprecipitated CAK was incubated in the pre sence of cold ATP
and GST-CDK6, with or witho ut cyclin Dl. The reaction was then
assayed for kinase activity usin g a purified GST-Rb protein as sub-
stra te. In lan es 5 of both pan els, a GST-CDK6 protein mu ta ted at
th reonine 177 (threonine -> a lanine, GST-CDK6 T177A ) was used .
protein (Fig. 3, bottom panel). To prove that CDK6 phosphoryl-
at ion by CAK occurs at th e unique sit e at th reonine at posit ion
177 th at is homologous to Thr-160 in CDK2 and Th r-161 in
CDC2, we used site -directed mutagenesis to replace Thr-177 by
Ala . When GST-CDK6 Ti n A was treated wit h immunopre -
cipitated CAK, no phosphorylation of the mu tan t CDK6 protein
(Fig. 3, top panel) or Rb kinase acti vity (Fig. 3, bottom pa nel)
was detected . The se data show that CDK6 is activated thro ugh
phosphorylation by CAK, a nd that this phosph oryla tion is en -
hanced by cyclin Dl.
We then tested the CDK6-specilic inhibitor p iS , a homolog of
p16 (21), for it s effect on CDK6 phosphory lation by CAK. In our
experiment , the p i S protein and GST-cyclin Dl were first
mixed, then added to GST-CDK6. After 30 min of incubation,
the result an t complex was mixe d with immunopr ecipi tated
CAK an d assess ed for CAK-depen dent phosphorylation. Fig. 4
(top panel) shows that piS efficiently blocke d the CDK6 phos-
phorylation by CAK. When recombinant Rb protein was added
to the CDK6/pIS/cyclin D mixture after CAK activation, no Rb
phosp horylation was foun d (Fig . 4, botto m pa nel). Th ese data
show that , like CDK2 , CDK6 activation by CAK is also regu-
la ted by piS CDK inhibitor. Thus, we demonstrate that both
fami lies of CDK inhibito rs block CDK phosp horylation an d
activation by CAK and that this block is most likely thro ugh
the same mechanism: by rendering the CDKs inaccessible to
CAK.
During the prepa ration of this manuscript, Kato et al . (7)
reported that in mouse mac rophages addit ion of cyclic AMP
(cAMP) resu lted in growth arrest in mid-G. phase, whe re
CDK4 exerts its effect on Rb phosphoryla tion . The study of
events that take place aft er cAMP treatment revealed that
induction of the p27 CDK inhibitor blocked the CDK4 activa-
tion. Similar to our results , the authors did not find direct
inte ra ction of p27 with CAK; thus the inh ibition of CDK acti-
vation by p27 bound to CDK4-cyclin Dl complex was inferred.
Taken together, these data suggest th at, in addition to th e
block of CDK phosp horylation of downstream subst ra tes such
as Rb or histone HI , another genera l mechani sm by which
CDK inhibitors regulate the cell cycle is by preventing CDK
phosphory lation and activation by CAK.
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